FDA Renews Psychopharmacologic Drugs Advisory Committee
Published Date: 5/29/2026
Notice
Summary
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for two more years, keeping it active until June 4, 2028. This committee helps make sure psychiatric drugs are safe and effective, affecting drug makers, doctors, and patients. No new costs or big changes, just a smooth continuation of expert advice to keep mental health treatments on track.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clozapine REMS Participation Changed (2024)
The committee's 2024 recommendations informed the FDA's decision to no longer expect prescribers, pharmacies, and patients to participate in the Clozapine REMS program or to report absolute neutrophil count (ANC) blood test results before pharmacies dispense clozapine. That change reduced procedural obligations for prescribers, pharmacies, and patients related to clozapine access.
Psychiatric Advisory Panel Renewed
The FDA renewed the Psychopharmacologic Drugs Advisory Committee for an additional two years, with the new charter in effect until June 4, 2028. The committee will continue to provide expert advice aimed at ensuring psychiatric drugs are safe and effective, affecting drug makers, prescribers, and patients; the notice states there are no new costs or major changes with this renewal.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10673 — Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest
The U.S. International Trade Commission got a complaint from Caterpillar about some heavy machinery parts being imported and sold unfairly by Doosan Bobcat companies around the world. They want to stop these imports and sales while the case is reviewed, which could affect businesses and buyers soon. The public and other groups have a chance to share their thoughts before any decisions are made.
Next: 2026-10676 — Caribou-Targhee National Forest; Wyoming; Amendment to the 1997 Land Management Plan for the Targhee National Forest
The Forest Service is updating the 1997 Targhee National Forest Plan to allow the Grand Targhee ski resort to expand by changing how 694 acres of forest land are used. This affects local outdoor lovers and businesses by turning some protected areas into special recreation zones. People have 60 days to raise any concerns before the changes get final approval.